# US 2015/0105430 A1 · Methods of treating or preventing neuropathic pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105430 A1
- Document ID: US20150105430A1
- Status: Published application
- Kind: A1
- Application number: 14/577,159
- Filed: 2014-12-19
- Published: 2015-04-16
- Earliest claimed: 2010-07-30
- Assignees: Toray Industreis, Inc.
- Applicants: Toray Industreis, Inc.
- Inventors: Naoki Izumimoto; Hidenori Mochizuki
- Web page: https://patentgrep.com/patent/US20150105430A1

## CPC

- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/195: having an amino group
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/415: 1,2-Diazoles
- A61K 31/421: 1,3-Oxazoles, e.g. pemoline, trimethadione
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/426: 1,3-Thiazoles
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method treats or prevents neuropathic pain with a synergistically-enhanced analgesic effect at a dose at which a calcium channel α2δ ligand does not produce any side effects as well as which agent does not produce any new side effects on the central nervous system. The therapeutic agent or a prophylactic agent used in the method includes as effective ingredients a cyclohexane derivative or a pharmaceutically acceptable salt thereof or a prodrug thereof, and a calcium channel α2δ ligand.

## Claims

### Claim 1

A method of treating or preventing neuropathic pain comprising separately administering a therapeutically or prophylactically effective amount of a cyclohexane derivative represented by Formula (I) below:
wherein
A is a substituent represented by Formula (IIa) or (IIb):
R1 and R2 are each independently a hydrogen atom, a chlorine atom, a C1-C3 haloalkyl group, a C1-C4 alkyl group or a C1-C4 alkoxy group;
R3 is a hydrogen atom or a chlorine atom; R4 is a fluorine atom, a hydroxymethyl group or a hydroxyl group;
R5 and R6 are each independently a hydrogen atom, a fluorine atom, a C1-C3 haloalkyl group, a carboxyl group, a methoxycarbonyl group, an ethoxycarbonyl group, a C1-C4 alkoxy group, a hydroxyl group or a C2-C5 alkylcarbonyloxy group, or optionally together form an oxo group;
R7 and R8 are each independently a hydrogen atom or a fluorine atom;
Y is an oxygen atom or a sulfur atom; and
Z is a nitrogen atom or a methine group or a pharmaceutically acceptable salt thereof or a prodrug thereof, and a calcium channel α2δ ligand.

### Claim 2 (depends on 1)

The method according to claim 1, wherein R1 and R2 are each independently a trifluoromethyl group, a methyl group or a methoxy group.

### Claim 3 (depends on 1)

The method according to claim 1, wherein R3 is a hydrogen atom.

### Claim 4 (depends on 1)

The method according to claim 1, wherein R4 is a hydroxymethyl group or a hydroxyl group.

### Claim 5 (depends on 1)

The method according to claim 1, wherein R5 and R6 are each independently a hydrogen atom, a fluorine atom, a trifluoromethyl group, a carboxyl group, a methoxy group, a hydroxyl group or an acetyloxy group, or optionally together form an oxo group.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said calcium channel α2δ ligand is pregabalin or gabapentin.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the cyclohexane derivative and the calcium channel α2δ ligand are administered at the same time.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the cyclohexane derivative and the calcium channel α2δ ligand are administered one after the other.
